From chemistry-request -8 at 8- ccl.net Wed Nov 19 16:39:45 2003
Received: from MMSSERVER.chla.usc.edu (chl179129.usc.edu [128.125.179.129])
	by server.ccl.net (8.12.8/8.12.8) with ESMTP id hAJLdDRW015764
	for <chemistry-.at.-ccl.net>; Wed, 19 Nov 2003 16:39:14 -0500
Received: from 10.3.1.165 by MMSSERVER.chla.usc.edu with ESMTP (CHLA
 SMTP Relay (MMS v5.5.3)); Wed, 19 Nov 2003 13:40:45 -0700
Received: by NTSMTP01 with Internet Mail Service (5.5.2653.19) id
 <WDP2XV3T>; Wed, 19 Nov 2003 13:38:28 -0800
Message-ID: <73564B8DE398D61180500008C75D7E49033E5DEC /at\NTMAIL03>
From: "Pandey, Jaya" <JPandey-.at.-chla.usc.edu>
To: "'chemistry-.at.-ccl.net'" <chemistry-.at.-ccl.net>
Subject: Peptidomimetics
Date: Wed, 19 Nov 2003 13:38:26 -0800
MIME-Version: 1.0
X-Mailer: Internet Mail Service (5.5.2653.19)
X-WSS-ID: 13A53CD7794867-01-01
Content-Type: text/plain
Content-Transfer-Encoding: 7bit
X-Spam-Status: No, hits=0.0 required=7.0
	tests=none
	version=2.55
X-Spam-Checker-Version: SpamAssassin 2.55 (1.174.2.19-2003-05-19-exp)

Dear All,

What criterias one should follow to design the peptide analogues of a
membrane receptor in order to bring the effect of a  toxic ligand down? I
designed few but instead of decreasing the effect somehow they are
potentiating the effect of the toxin!!

If any one has any advice or experience in this please help!

Thanks,

Jaya